In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

For Dot-Coms, First Mover Disadvantage

Executive Summary

The implications that the Global Health Exchange, the new Internet portal formed by a group of leading medical device firms, is, in some sense, now a market maker, underscores one of the clear conclusions that can be drawn from what has been a crazy year for e-health companies. Virtually everyone underestimated the power of the entrenched entities to, at once, defend their turf and develop their own responses to the Internet opportunity. B2B dot-coms burst on the scene arguing that the current hospital supply chain players had failed to do the job and that they would provide an alternative with new models for doing product procurement more efficiently--trading exchanges, for example, or on-line auctions or RFPs. But the dot-coms quickly faced a chicken-and-egg problem--no matter how ingenious their business model, customers wouldn't sign up without proof that there were suppliers on board and suppliers wouldn't join in without evidence that the site would have customers valued by both sides. This is the opening that the Global Exchange hopes to exploit, and ironically, while the dot-coms early on debated the importance of brand names and first mover advantage, it now seems clear that the ultimate advantages already belonged to those established players that the dot-coms first tried to challenge and later sought to team up with.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

IV001510

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel